• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    TransCode Therapeutics, Inc. - Common Stock (NQ:RNAZ)

    8.090 +0.260 (+3.32%)
    Streaming Delayed Price Updated: 11:49 AM EDT, May 4, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,489
    Open 7.920
    Bid (Size) 7.830 (400)
    Ask (Size) 8.350 (100)
    Prev. Close 7.830
    Today's Range 7.830 - 8.090
    52wk Range 6.083 - 20.99
    Shares Outstanding 833,683
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Appoints Scientific Advisory Board Chair, Signs Research Agreement With Michigan State University
    Via Investor Brand Network
    MissionIRNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Secures Up to $20 Million Financing Agreement
    Via Investor Brand Network

    Performance

    YTD
    +9.3%
    +9.3%
    1 Month
    -5.9%
    -5.9%
    3 Month
    -13.0%
    -13.0%
    6 Month
    -23.0%
    -23.0%
    1 Year
    -43.6%
    -43.6%

    More News

    Read More
    BioMedNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Secures Exclusive Global License to Three Unleash Immuno-Oncolytics Drug Candidates
    Via Investor Brand Network
    BioMedNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Announces Publication On Tumor-Selective RIG-I Immunotherapy Approach
    Via Investor Brand Network
    BioMedNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Submits IND Amendment for Planned Phase 2a Trial of TTX-MC138 in Colorectal Cancer
    Via Investor Brand Network
    BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Publishes Preclinical Data Supporting TTX-MC138 for Glioblastoma
    Via Investor Brand Network
    InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Appoints Jack E. Stover to Board of Directors
    Via Investor Brand Network
    News headline image
    The market is filled with gapping stocks in Thursday's session. ↗
    Via Chartmill
    InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Quantum Leap Launch Collaboration to Evaluate TTX-MC138 in PRE-I-SPY Trial
    Via Investor Brand Network
    InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Appoints Dr. Michel Janicot as Senior Development Officer
    Via Investor Brand Network
    BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Completes Phase 1a Trial of TTX-MC138, Advancing to Phase 2 Evaluation
    Via Investor Brand Network
    News headline image
    MAGA Stocks Undercard: MYSE, XBIO, ATON, ACXP, RDZN – Innovators Driving Next Tech, Blockchain, AI Wave – More Stocks Inside
    Via AB Newswire
    Topics Artificial Intelligence Intellectual Property
    InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Acquires Polynoma, Secures $25 Million Investment from CK Life Sciences to Advance Phase 2 Trial of TTX-MC138
    Via Investor Brand Network
    News headline image
    TransCode Makes Bold Bet On Melanoma Vaccine With Polynoma Buyout ↗
    Via Benzinga
    News headline image
    TransCode Therapeutics To Acquire Polynoma, Receive $25M Investment To Advance Key Asset ↗
    Via Stocktwits
    News headline image
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Why FedEx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
    Via Benzinga
    News headline image
    Which stocks are experiencing notable movement on Wednesday? ↗
    Via Chartmill
    News headline image
    These stocks are gapping in today's session ↗
    Via Chartmill
    News headline image
    These stocks that are showing activity before the opening bell on Wednesday. ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
    Via Benzinga
    InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Appoints RNAi Pioneer Phillip Zamore to Scientific Advisory Board
    Via Investor Brand Network

    Frequently Asked Questions

    Is TransCode Therapeutics, Inc. - Common Stock publicly traded?
    Yes, TransCode Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does TransCode Therapeutics, Inc. - Common Stock trade on?
    TransCode Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for TransCode Therapeutics, Inc. - Common Stock?
    The ticker symbol for TransCode Therapeutics, Inc. - Common Stock is RNAZ on the Nasdaq Stock Market
    What is the current price of TransCode Therapeutics, Inc. - Common Stock?
    The current price of TransCode Therapeutics, Inc. - Common Stock is 8.090
    When was TransCode Therapeutics, Inc. - Common Stock last traded?
    The last trade of TransCode Therapeutics, Inc. - Common Stock was at 05/04/26 11:49 AM ET
    What is the market capitalization of TransCode Therapeutics, Inc. - Common Stock?
    The market capitalization of TransCode Therapeutics, Inc. - Common Stock is 6.74M
    How many shares of TransCode Therapeutics, Inc. - Common Stock are outstanding?
    TransCode Therapeutics, Inc. - Common Stock has 7M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.